Trial · NCT01911273
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Tumor Progression (TTP) | PF-03446962 Plus BSC | NA | 95% Confidence Interval NA to NA | Months | |
| Time to Tumor Progression (TTP) | BSC Alone | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) | PF-03446962 Plus BSC | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) | BSC Alone | NA | 95% Confidence Interval NA to NA | Months | |
| Progression-Free Survival (PFS) | PF-03446962 Plus BSC | NA | 95% Confidence Interval NA to NA | Months | |
| Progression-Free Survival (PFS) | BSC Alone | NA | 95% Confidence Interval NA to NA | Months | |
| Objective Response Rate (ORR) - Percentage of Participants With Objective Response | PF-03446962 Plus BSC | NA | Percentage of Participants | ||
| Objective Response Rate (ORR) - Percentage of Participants With Objective Response | BSC Alone | NA | Percentage of Participants | ||
| Percentage of Participants With Disease Control Rate (DCR) at 16 Weeks | PF-03446962 Plus BSC | NA | 95% Confidence Interval NA to NA | Percentage of Participants | |
| Percentage of Participants With Disease Control Rate (DCR) at 16 Weeks | BSC Alone | NA | 95% Confidence Interval NA to NA | Percentage of Participants | |
| Change From Baseline in Functional Assessment of Cancer Therapy-Hepatobiliary Questionnaire (FACT-Hep) | PF-03446962 Plus BSC | NA | Standard Deviation NA | Units on scale | |
| Change From Baseline in Functional Assessment of Cancer Therapy-Hepatobiliary Questionnaire (FACT-Hep) | BSC Alone | NA | Standard Deviation NA | Units on scale | |
| Maximum Serum Concentration (Cmax) | PF-03446962 Plus BSC | NA | Standard Error NA | microgram per milliliter (mcg/mL) | |
| Trough Serum Concentration of PF-03446962 (Ctrough) | PF-03446962 Plus BSC | NA | Standard Error NA | mcg/mL | |
| Number of Participants With Human Anti-Human Antibodies (HAHA) | PF-03446962 Plus BSC | NA | Participants | ||
| Ratio to Baseline of Serum Circulating Protein Concentration | PF-03446962 Plus BSC | NA | Percentage | ||
| Observed Serum Concentration of Circulating Protein | PF-03446962 Plus BSC | NA | mcg/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01911273/results